• Alias                                 (According to NCBI)

• AAG4,
• APOJ,
• CLI,
• KUB1,
• MGC24903,
• SGP-2,
• SGP2,
• SP-40,
• TRPM-2,
• TRPM2
• ging-associated protein 4;
• apolipoprotein J;
• clusterin (complement lysis inhibitor, SP-40,40, sulfated glycoprotein 2, t
• estosterone-repressed prostate message 2, apolipoprotein J);
• complement lysis inhibitor;
• complement-associated protein SP-40;
• sulfated glycoprotein 2;
• testosterone-repressed prostate message 2

• Description   

  (According to SwissProt)

• Not yet clear. It is known to be expressed in a variety of tissues and it seems to be able to bind to cells, membranes and hydrophobic proteins. It has been associated with programmed cell death (apoptosis).

• Chromosomal location

  (According to NCBI, CGH: progenetix)

• Location: 8p21-p12
• Size: 17877 bp
• exons: Transcript variant 1 : 9 ; Transcript variant 2 : 8
• DNA sequence (Human): NC_000008.9

• CGH (8p21):  Losses (%) -28.5   Gain (%)  3.9  

• Mutations and SNPs (According to HGMD and SNP)

• HGMD : CLU
• SNPs: 1191

• m-RNA                       (According to NCBI and CGAP)

• mRNA sequence (Human):  

          Transcript variant 1 : NM_001831.2

          Transcript variant 2 : NM_203339.1

• Size:

          Transcript variant 1 : 2859

          Transcript variant 2 : 2979

• cDNA libraries: CLU

• Protein                        (According to SwissProt, Swiss2D, PDB )

• Size:449 amino acids; 52,495 Da

• Subcellular location: Secreted

• Protein domains

• Protein sequence (Human): P10909

• Homologous genes:  1382

• 2D PAGE: CLU

• 3D Structure:  

• PTM: Glycoprotein

• Pathways and interactions (According to BioCarta, IntAct)

• Pathway:

• Protein interactions: CLU

• Tissue

  (According to GeneNote, PubMed, HPA)

• Tissue expression: PubMed Reference
• Human Protein Atlas (HPA): HPA000572

• Clinical                            (According to OMIM, PubMed)

• OMIM : 185430
• PubMed:    Early detection      Diagnosis         Prognosis        Therapy